Technical Analysis for IMCR - Immunocore Holdings plc

Grade Last Price % Change Price Change
F 48.36 -1.31% -0.64
IMCR closed down 1.31 percent on Friday, February 26, 2021, on 37 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat
Historical IMCR trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Hot IPO Pullback Bullish Swing Setup -1.31%
Narrow Range Bar Range Contraction -1.31%
Hot IPO Pullback Bullish Swing Setup -1.67%
Inside Day Range Contraction -1.67%
Multiple of Ten Bearish Other 1.58%
Shooting Star Candlestick Bearish -4.77%
Doji - Bearish? Reversal -4.77%
Older End-of-Day Signals for IMCR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Immunocore Holdings plc Description

Immunocore Holdings Limited, a late-stage biotechnology company, develops immunotherapies for the treatment of oncology, infectious, and autoimmune diseases. The company's lead oncology therapeutic candidate is tebentafusp, which is in a randomized Phase III clinical trial in patients with previously untreated metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung, gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising breast, endometrial, ovarian, and small cell lung cancers; and GSK01 that is in a Phase I clinical trial. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Immunotherapy Oncology Autoimmune Diseases Breast Cancer Virotherapy Immunotherapies Oncolytics Biotech Solid Tumor Cancers Treatment Of Autoimmune Diseases Small Cell Lung Cancers Chronic Hepatitis B Virus Immunocore Immunosuppression Pelareorep

Is IMCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 61.979
52 Week Low 39.02
Average Volume 173,761
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 48.48
Average True Range 5.62
ADX 0.0
+DI 20.08
-DI 11.67
Chandelier Exit (Long, 3 ATRs ) 45.12
Chandelier Exit (Short, 3 ATRs ) 55.87
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.17
MACD Signal Line -0.08
MACD Histogram -0.0898
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 53.36
Resistance 3 (R3) 53.38 51.74 52.53
Resistance 2 (R2) 51.74 50.46 51.73 52.25
Resistance 1 (R1) 50.05 49.67 49.22 50.03 51.97
Pivot Point 48.40 48.40 47.99 48.39 48.40
Support 1 (S1) 46.71 47.13 45.89 46.69 44.75
Support 2 (S2) 45.07 46.34 45.06 44.47
Support 3 (S3) 43.38 45.07 44.19
Support 4 (S4) 43.36